Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At-home genetic tests scrutinized

This article was originally published in The Gray Sheet

Executive Summary

"No at-home genetic tests have been reviewed by the FDA, and the FDA has not evaluated the accuracy of their claims," writes the Federal Trade Commission in a July 27 consumer fact sheet. FTC notes that at-home genetic tests, which range in price from $295 to $1,200, are not backed by "valid scientific studies" showing their safety and efficacy. "Because of the complexities involved in both the testing and the interpretation of the results, genetic tests should be performed in a specialized laboratory," with results interpreted by a clinician, the fact sheet notes. FTC has been criticized for its limited oversight of genetic testing claims (1"The Gray Sheet" Nov. 3, 2003, p. 16)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel